Decramer M, Brusselle G, Buffels J, Corhay J L, De Backer W, Degryse J M, Janssens W, Marchand E, Van den Brande P, Vincken W, Gayan-Ramirez G, Van Craenendonck V, Vandenberghe H, De Vuyst P
UZ Leuven, Respiratory Division, Leuven, Belgium.
Ghent University Hospital, Department of Respiratory Medicine, Ghent, Belgium.
Acta Clin Belg. 2013 Sep-Oct;68(5):325-40. doi: 10.2143/ACB.3403.
Chronic Obstructive Pulmonary Disease (COPD) is underestimated, underdiagnosed and often under-treated in the general population. A survey of 17 structured questions, delivered to all Belgian pulmonary physicians (PPs) (116 responses), evaluated diagnosis and treatment strategies in accordance with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 2010 and assessed opinions about the importance of diurnal variation of COPD symptoms. All COPD diagnoses (37% new cases) were spirometry confirmed. Main diagnostic parameters were symptoms (99%), external risk factors (99%), clinical examination (97%), exacerbations (96%) and patient mobility (96%). FEV1 (forced expiratory volume in 1s) (97%) or FEV1/FVC (ratio of FEV1 to forced vital capacity) (93%) were used most to assess diagnosis and severity. The 3 most important therapeutic objectives were symptom relief, preventing exacerbations, and improving quality of life; if these were not reached, the preferred strategy (60% of PPs) was adding another medication. Treatment strategies varied with COPD stage: short-acting beta2-agonists (90%) and short-acting anti-cholinergics (59%) were used for GOLD I disease, whereas for higher stages long-acting beta2-agonists (36-48%) and long-acting anti-cholinergics (79%) were given with inhaled corticosteroids (21-67%). Symptoms were perceived to vary throughout the day, affecting quality of life (97%) and mobility (89%). In particular, respiratory symptoms were more severe in the morning (51-92%), leading PPs to adapt treatment (69%). This survey demonstrated that management of COPD by PPs in Belgium is generally in line with the GOLD guidelines 2010 and that they perceive morning symptoms as being frequent and having an impact on patient's life.
慢性阻塞性肺疾病(COPD)在普通人群中存在被低估、诊断不足且治疗往往不充分的情况。一项针对所有比利时肺科医生(PPs)的包含17个结构化问题的调查(收到116份回复),根据2010年慢性阻塞性肺疾病全球倡议(GOLD)指南评估了诊断和治疗策略,并评估了关于COPD症状日变化重要性的观点。所有COPD诊断(37%为新病例)均经肺功能测定确认。主要诊断参数为症状(99%)、外部风险因素(99%)、临床检查(97%)、急性加重(96%)和患者活动能力(96%)。FEV1(一秒用力呼气容积)(97%)或FEV1/FVC(FEV1与用力肺活量之比)(93%)最常用于评估诊断和严重程度。3个最重要的治疗目标是缓解症状、预防急性加重和改善生活质量;如果这些目标未达成,首选策略(60%的肺科医生)是加用另一种药物。治疗策略因COPD阶段而异:短效β2受体激动剂(90%)和短效抗胆碱能药物(59%)用于GOLD I期疾病,而对于更高阶段,长效β2受体激动剂(36 - 48%)和长效抗胆碱能药物(79%)与吸入性糖皮质激素(21 - 67%)联合使用。症状被认为在一天中有所变化,影响生活质量(97%)和活动能力(89%)。特别是,呼吸道症状在早晨更严重(51 - 92%),导致肺科医生调整治疗(69%)。这项调查表明,比利时肺科医生对COPD的管理总体上符合2010年GOLD指南,并且他们认为早晨症状频繁且对患者生活有影响。